Destiny Tech100の空売り状況は、投資家がDestiny Tech100の株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Destiny Tech100 (NYSE:DXYZ) 株価情報, 空売り情報

Destiny Tech100 Inc is a non-diversified, closed-end management investment company. It invests in a portfolio of what is believed to be 100 of the top venture-backed private technology companies.

Destiny Tech100 Inc

<p>Copart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRT#NASDAQ">CPRT</a>) reported quarterly earnings of $0.37 per share which met the analyst consensus estimate.  The company reported quarterly sales of $1.146 billion which beat the analyst consensus estimate of $1.100 billion by 4.19 percent.  This is a 12.35 percent increase over sales of $1.020 billion the same period last year.</p>


Earnings

Earnings Beats

News

CPRT

Copart Q1 2025 GAAP EPS $0.37, Inline, Sales $1.146B Beat $1.100B Estimate

<p>Regulators are looking to block <strong>Google</strong> <a href="https://www.benzinga.com/news/large-cap/23/10/35474706/googles-ai-ambitions-grow-with-major-investment-in-openai-rival-anthropic">from investing $2 billion</a> in <strong>Antrophic</strong>, a <strong>Jeff Bezos</strong>-backed rival to artificial intelligence (AI) innovator <strong>OpenAI</strong>. </p>
<p><strong>What Happened</strong>: The U.S. Department of Justice (DOJ) recommended in <a href="https://www.benzinga.com/tech/24/11/42105079/googles-unlawful-behavior-stifles-market-entry-for-rivals-doj-says-alphabet-must-sell-chrome-to-end-search-monopoly">a court filing Wednesday</a> that <strong>Alphabet Inc</strong>&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) <strong>Google </strong>divest its Chrome browser to dismantle its monopoly on online search. </p>
<p>It doesn&#8217;t end there. Google should be barred from doing any deals with companies that control where consumers search for information, regulators say. That includes AI products. This puts Google's Anthropic investment at risk, according to <a href="https://www.bloomberg.com/news/articles/2024-11-21/us-justice-department-seeks-to-unwind-google-s-anthropic-deal">Bloomberg</a>, citing unnamed sources.</p>
<p><strong><strong>Also Read: <a href="https://www.benzinga.com/news/earnings/earnings-beats/24/11/42121215/nvidia-post-earnings-jitters-can-nvda-stock-regain-its-ai-fueled-momentum">Nvidia&#8217;s Post-Earnings Jitters: Can NVDA Stock Regain Its AI-Fueled Momentum?</a></strong></strong></p>
<p>Google boasts over 91% global market share when it comes to online search, per&nbsp;<a href="https://gs.statcounter.com/search-engine-market-share" target="_blank" rel="noreferrer noopener">GlobalStats</a>.&nbsp;</p>
<p><strong>Why It Matters</strong>: Google needs Anthropic, or startups like it. Without it, Google is at a disadvantage, considering every major tech company is essentially in an AI arms race. </p>
<p>Since OpenAI&#8217;s ChatGPT launch in late 2022, tech giants have heavily invested in AI startups.</p>
<p>But Google&#8217;s Anthropic deal is raising concerns overseas as well.</p>
<p>Last month, U.K. antitrust officials announced an investigation into whether Google&#8217;s pursuit of Anthropic<strong> </strong><a href="https://www.gov.uk/cma-cases/alphabet-inc-google-llc-slash-anthropic-merger-inquiry" target="_blank" rel="noreferrer noopener">could harm competition</a>. </p>
<p>Meanwhile, <strong>Amazon.com Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) managed to avoid scrutiny. <a href="https://www.benzinga.com/m-a/24/09/41067395/amazons-partnership-with-jeff-bezos-backed-anthropic-gets-green-signal-from-uk-competition-watchdog" target="_blank" rel="noreferrer noopener">The UK&#8217;s competition regulator</a> recently approved the partnership between Amazon and Anthropic, despite the Seattle-based company&#8217;s significant $4 billion investment in the company.</p>
<p>Britain&#8217;s Competition and Markets Authority (CMA) confirmed the partnership does not fall under its jurisdiction.</p>
<p><strong>Microsoft Corp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) also appeased regulators when it <a href="https://www.benzinga.com/markets/equities/24/07/39703459/microsoft-relinquishes-observer-role-on-openais-board-says-it-is-confident-in-companys-direction" target="_blank" rel="noreferrer noopener">relinquished its board observer</a> role at OpenAI. The Redmond, Washington-based company invested over $10 billion in the AI startup.</p>
<p><strong>What&#8217;s Next</strong>: A decision on whether the UK will require further investigation is expected by Dec. 19.</p>
<p>In the U.S., Google plans to appeal Judge <strong>Amit Mehta</strong>&#8216;s <a href="https://www.benzinga.com/government/24/08/40169996/alphabet-loses-antitrust-suit-over-google-search-dominance-report">antitrust ruling in August</a>. </p>
<p>Mehta&#8217;s decision could ultimately lead to Google divesting segments of its business, <a href="https://www.benzinga.com/government/regulations/24/11/42119020/alphabet-bleeds-over-120-billion-in-market-value-eyes-worst-day-in-10-months-after-doj-demands-google-chrome-sale">including Chrome</a>.</p>
<p><strong>Price Action:</strong> Alphabet was down 4.5% to $169.24 on Thursday.</p>
<p><strong>Now Read:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42121525/microstrategy-surges-674-in-2024-5-etfs-that-benefit-from-mstrs-bitcoin-driven-growth">MicroStrategy Surges 674% In 2024: 5 ETFs That Benefit From MSTR&#8217;s Bitcoin-Driven Growth</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Politics

Tech

AMZN

GOOG

GOOGL

MSFT

Google, Anthropic Deal In Jeopardy As US Justice Department Looks To Snap Online Search Monopoly

Contracts

SNOA

Sonoma Pharmaceuticals Terminates Agreement With EMC Pharma After It Did Not Meet Minimum Purchase Requirements

Buybacks

EGAN

eGain Board Approves Extension To Stock Repurchase Program From Nov. 14 Until The Earlier Of The Date The Aggregate Amount Of Shares That Can Be Repurchased Under The Stock Repurchase Program Have Been Repurchased And November 14, 2025

<p><i>Authorization is based on results from the Phase 3 CARTITUDE-4 (MMY3002) study, which showed treatment with CARVYKTI&#xAE; reduced the risk of disease progression or death by 74 per cent compared to standard of care.1</i></p>
<p>TORONTO, Nov. 21, 2024 /CNW/ - Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced today that Health Canada has issued a Notice of Compliance (NOC) for CARVYKTI&#xAE; (ciltacabtagene autoleucel) for the treatment of adult patients with multiple myeloma who have received one to three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide.1&nbsp;With this approval, CARVYKTI&#xAE; becomes the first and only B-cell Maturation Antigen&nbsp;(BCMA)-targeted therapy approved for the treatment of patients with multiple myeloma as early as second line.</p>
<p>CARVYKTI&#xAE; previously received a Notice of Compliance with conditions (NOC/c) from Health Canada for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody, and who are refractory to their last treatment.1</p>
<p>Canada's Drug Agency (CDA-AMC) has recently recommended CARVYKTI&#xAE; for reimbursement with conditions for eligible patients who have received one to three prior lines of therapy. In its rationale for the recommendation, CDA-AMC pointed out that the CARTITUDE-4 trial demonstrated that treatment with CARVYKTI&#xAE;, compared to standard of care, was associated with statistically significant and clinically meaningful improvements in progression-free survival (PFS) in eligible patients. This builds on their prior recommendation for reimbursement with conditions for CARVYKTI&#xAE; in 2023 in eligible patients who have received at least three prior lines of therapy, based on the results of the CARTITUDE-1 trial. Johnson &amp; Johnson is actively working with the pan-Canadian Pharmaceutical Alliance to negotiate reimbursement for CARVYKTI&#xAE; to enable public access.</p>


Biotech

General

Johnson & Johnson Announces Health Canada Authorizes CARVYKTI For Patients With Relapsed Or Refractory Multiple Myeloma Who Have Received 1-3 Prior Lines Of Therapy, Including A Proteasome Inhibitor And An Immunomodulatory Agent, And Who Are Refractory To Lenalidomide

BGC Group's Howard Lutnick To Divest Interests And Step Down From Roles At Cantor, BGC, And Newmark Pending Senate Confirmation; Corporate Structure To Remain Unchanged With John Abularrage, Jean-Pierre Aubin, And Sean Windeatt Recommended As Co-CEOs

<p>Myers Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYE#NYSE">MYE</a>), a leading manufacturer of a wide range of polymer and metal products and distributor for the tire, wheel and under-vehicle service industry (the "Company" or "Myers"), today announced that its Board of Directors (the "Board") has appointed Aaron M. Schapper as the Company's new President and Chief Executive Officer, effective January 1, 2025. Mr. Schapper will succeed Dave Basque, who has been serving as Myers' Interim President and CEO since September 9, 2024, and who will return to his role as Vice President, Special Projects. Mr. Schapper will also join the Board in January.</p>


Management

Myers Industries Appoints Aaron Schapper As President, Chief Executive Officer And Director Effective January 1, 2025; Dave Basque, Who Has Been Serving As Myers' Interim President And CEO Since September 9, 2024, Will Return To His Role As Vice President, Special Projects

<p><i><strong>Oral peptide with biologics-like high potency and spectrum of activity against three therapeutically relevant dimeric forms of IL-17 (AA, AF and FF)</strong></i></p>
<p><i><strong>IND enabling studies underway, with Phase I initiation expected in Q425</strong></i></p>


PTGX

Protagonist Selects PN-881 As Development Candidate For Treatment Of Immune-Mediated Skin Disease

Alta Global Group Files Request For Withdrawal Of Its Registration Statement On Form F-1 With SEC, Initially Filed On September 5, 2024

<p><a href="https://storage.courtlistener.com/recap/gov.uscourts.txnd.395430/gov.uscourts.txnd.395430.30.0.pdf" title="https://storage.courtlistener.com/recap/gov.uscourts.txnd.395430/gov.uscourts.txnd.395430.30.0.pdf">https://storage.courtlistener.com/recap/gov.uscourts.txnd.395430/gov.uscourts.txnd.395430.30.0.pdf</a><br />&nbsp;</p>


Hims & Hers Health, Inc. Class A Common Stock

HIMS

Shares Of Hims & Hers Health See Volume; Traders Circulate Court Filing Regarding Shortage Of Lilly's Tirzepatide Shortage, Parties Agree To Maintain Stay As Ordered By Court In October 2024, With Joint Status Report Due By December 19, 2024, Or Within Seven Days Of FDA's New Decision

<p>The earnings results for <strong>Logility Supply Chain</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGTY#NASDAQ">LGTY</a>) for Q2 were made public on Thursday, November 21, 2024 at 04:05 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>Logility Supply Chain beat estimated earnings by 22.0%, reporting an EPS of $0.11 versus an estimate of $0.09.</p>
<p>Revenue was down $404 thousand from the same period last year.</p>
<h3>Historical Earnings Summary</h3>
<p>During the previous quarter, the company beat on EPS by $0.04, leading to a 8.0% increase share price change the next day.</p>
<p>Here's a look at Logility Supply Chain's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.08</td>
<td>0.08</td>
<td>0.07</td>
<td>0.09</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.12</td>
<td>0.12</td>
<td>0.19</td>
<td>0.08</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>25.26M</td>
<td>25.12M</td>
<td>24.81M</td>
<td>28.00M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>26.19M</td>
<td>25.39M</td>
<td>25.54M</td>
<td>25.69M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Logility Supply Chain <a href="https://www.benzinga.com/quote/LGTY/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


LGTY

Logility Supply Chain: Q2 Earnings Insights

Offerings

MODD

Modular Medical Announces Proposed Public Offering; Terms Not Disclosed

<p><strong>Elastic</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) announced its Q2 earnings on Thursday, November 21, 2024 at 04:05 PM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>Elastic beat estimated earnings by 55.00000000000001%, reporting an EPS of $0.59 versus an estimate of $0.38.</p>
<p>Revenue was up $54.75 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>During the previous quarter, the company beat on EPS by $0.1, leading to a 26.0% drop share price change the next day.</p>
<p>Here's a look at Elastic's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.25</td>
<td>0.20</td>
<td>0.31</td>
<td>0.24</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.35</td>
<td>0.21</td>
<td>0.36</td>
<td>0.37</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>344.70M</td>
<td>329.48M</td>
<td>320.29M</td>
<td>304.11M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>347.42M</td>
<td>335.00M</td>
<td>327.96M</td>
<td>310.61M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Elastic <a href="https://www.benzinga.com/quote/ESTC/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ESTC

Earnings Summary: Elastic Q2

Health Care

Sonoma Pharmaceuticals Relaunches Its Prescription Dermatology And Eye Care Product Lines In The US

Warner Music Group Files For Mixed Shelf; Size Not Disclosed

<p>Farrell will continue to report directly to Nazar Khan, Chief Technology Officer of TeraWulf.</p>


WULF

TeraWulf Promotes Sean Farrell To COO, Effective Immediately

VRPX

Virpax Pharmaceuticals Announces An Agreement With The U.S. HHS Department An Extension Of Its Cooperative Research And Development Agreement

Guidance

Elastic Sees FY25 Adj. EPS $1.68-$1.72 Vs $1.54 Est.; Revenue $1.451B-$1.457B Vs $1.448B Est.

WKHS

Workhorse Delivers First W56 Electric Step Van Outside California To Minneapolis-Based FedEx Ground Provider NorthStar Courier Through Ziegler Truck Group

Elastic Sees Q3 Adj. EPS $0.46-$0.48; Revenue $367M-$369M

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>You&rsquo;ve heard about <a href="https://investorplace.com/stock-types/meme-stocks/">meme stocks</a>, but have you heard of meme funds? With the <strong>Destiny Tech100</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/dxyz-stock-quote/"><strong>DXYZ</strong></a>) fund, you can diversify your portfolio into unusual, high-risk assets. It&rsquo;s not something you want to allocate too much of your capital towards, but audacious investors might want to give DXYZ stock a try.</p>



<p>I&rsquo;m calling it a meme fund because the Destiny Tech100 share price rallied sharply before pulling back. So, you might be able to invest in the Destiny Tech100 fund at a comparatively favorable price today. But don&rsquo;t hit that buy button until you&rsquo;ve gotten the need-to-know details about Destiny Tech100, which I&rsquo;ll give you right now.</p>



<h2>Invest in the Uninvestable With Destiny Tech100</h2>



<p>Do you want to buy common-stock shares of <strong>SpaceX</strong> and <strong>OpenAI</strong>? Good luck with that, as those currently aren&rsquo;t publicly traded companies. However, as <em>Bloomberg</em> reported, you can get <a href="https://finance.yahoo.com/news/destiny-ceo-calls-private-tech-143003780.html">indirect portfolio exposure</a> to those hot-topic businesses through DXYZ stock.</p>



<p>Destiny Tech100 invests in SpaceX, OpenAI and other forward-thinking businesses with technology angles. It&rsquo;s a new fund that just started trading on the <strong>New York Stock Exchange</strong> <a href="https://finance.yahoo.com/news/nyse-welcomes-destiny-tech100-dxyz-130000609.html">on March 26</a> of this year.</p>



<p>Furthermore, an innovation-and-impact-focused company called <strong>Destiny XYZ Inc.</strong> manages the Destiny Tech100 fund. The fund&rsquo;s purpose is to provide &ldquo;everyday investors access to many of the world&rsquo;s most exciting private businesses,&rdquo; including SpaceX, OpenAI, Stripe and Discord.</p>



<p>I dug around and found a Securities and Exchange Commission (SEC) filing that reveals some more of the Destiny Tech100 fund&rsquo;s <a href="https://finance.yahoo.com/sec-filing/DXYZ/0001398344-24-005739_1843974?nn=1">holdings</a>. </p>



<p>These are (or at least were, as of Dec. 31, 2023), for the most part, preferred shares of companies that most people won&rsquo;t easily be able to invest in, such as <strong>Axiom Space</strong>, <strong>Impossible Foods</strong> and <strong>Bolt Financial</strong>.</p>



<h2>Financial Faults, but a More Favorable Price</h2>



<p>That same SEC filing revealed some startling financial data about Destiny Tech100 (the company, not the fund). Specifically, Destiny Tech100 sustained a net investment loss of $2.939 million in 2022 and a loss of $2.852 million in 2023.</p>



<p>That&rsquo;s not a wonderful track record, I&rsquo;ll admit. This is the main reason I&rsquo;m warning investors to keep their DXYZ stock positions small, if they choose to invest in it at all.</p>



<p>Also, there&rsquo;s the share-price volatility to consider. The stock, which started trading not long ago, already has a 52-week range of <a href="https://finance.yahoo.com/quote/DXYZ?.tsrc=fin-srch">$8.25 to $105</a>.</p>



<p>Recently, Destiny Tech100 stock traded at around $13, so at least you wouldn&rsquo;t be chasing it near the top. If you&rsquo;re going to buy a meme stock (or meme fund, in this case), it&rsquo;s wise to wait until the risk-to-reward profile is favorable.</p>



<p>In other words, the meme-stock pop-and-drop cycle seems to already have taken place. Consequently, you might want to dip your toes in the water and buy a few reduced-price Destiny Tech100 shares.</p>



<h2>DXYZ Stock: Position Sizing Is Key</h2>



<p>The Destiny Tech100 fund enables access to otherwise uninvestable preferred stocks. The fund&rsquo;s holdings represent some very interesting, innovative, tech-focused businesses.</p>



<p>If you&rsquo;re on board with this and can accept a high level of risk, the Destiny Tech100 fund may be right for you. The key is to only hold a small number of DXYZ stock shares. That way, you won&rsquo;t be overexposed if the fund&rsquo;s value collapses in the coming months.</p>



<p><em>On the date of publication, David Moadel</em><em>&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;</em><em>The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a><em>.</em></p>
<div><p>David Moadel has provided compelling content &ndash; and crossed the occasional line &ndash; on behalf of Motley Fool, Crush the Street, Market Realist, TalkMarkets, TipRanks, Benzinga, and (of course) InvestorPlace.com. He also serves as the chief analyst and market researcher for Portfolio Wealth Global and hosts the popular financial YouTube channel Looking at the Markets.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/2024/05/meme-fund-mania-is-dxyz-stock-your-ticket-to-the-hottest-private-companies/">Meme Fund Mania: Is DXYZ Stock Your Ticket to the Hottest Private Companies?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Meme Fund Mania: Is DXYZ Stock Your Ticket to the Hottest Private Companies?

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>If you&rsquo;re a risk taker and into meme-<a href="https://investorplace.com/industries/technology/">tech stocks</a>, <strong>Destiny Tech100</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/dxyz-stock-quote/"><strong>DXYZ</strong></a>) is certainly an intriguing option to consider. This close-ended management investment, the DXYZ stock, <a href="https://destiny.xyz/tech100">operates as an ETF</a>, holding what managers believe are the &ldquo;top 100 high-growth tech companies.&rdquo; Notably, these companies are venture-backed and privately-listed, meaning investors can gain exposure to companies that may otherwise be unavailable on the private market. </p>



<p>Destiny XYZ Inc. manages the company and offers exposure to innovative companies like SpaceX and OpenAI. It began trading on March 26 and aims to provide everyday investors with access to exciting private businesses.</p>



<p>Here&rsquo;s everything you need to know about the DXYZ stock.</p>



<h2>The DXYZ Stock is a <strong>New NYSE Member</strong></h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/08/techstocks1600-300x169.png" alt="Close up of phone with creative forex chart on blue background. Trade, finance, technology and communication concept. 3D Rendering. Tech Stocks to Buy Before the Bull Market Returns. Tech Stocks to buy"><div>Source: Golden Dayz / Shutterstock.com</div></div><p>Destiny Tech100 <a href="https://www.businesswire.com/news/home/20240327776952/en/NYSE-Welcomes-Destiny-Tech100-DXYZ-Pioneering-Access-to-Tech-Innovation">debuted</a> on the New York Stock Exchange on March 26, 2024. Its opening price was $8.25, up 70.5% from the reference price of $4.84. Trading ranged from $8.25 to $30.48, closing at $9.00 with 540,000 shares traded. The company aims to provide investors access to private market growth opportunities in a public market setting, and has clearly seen very strong demand.</p>



<p>The company has revolutionized private-sector investing, making it more accessible and transparent. Destiny Tech100 offers opportunities previously unavailable to average investors and focuses on innovation and impact.</p>



<h2><strong>The Problem</strong> with the DXYZ Stock</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/shutterstock_1926453779-300x169.png" alt="top Tech stocks to watch : Double exposure of man's hands holding and using a phone and financial graph drawing. tech stocks"><div>Source: Peshkova / Shutterstock</div></div><p>The Destiny Tech100 fund, which went public in March, held shares in private giants like <strong>SpaceX</strong>, <strong>OpenAI</strong>, and <strong>Epic Games</strong>. This appeal was evident as these companies were typically inaccessible to the average investor. Moreover, it is also worth noting that the DXYZ stock is not just an average exchange-traded fund. It is also a closed-end management investment company, similar to an investment trust.</p>



<p>Debuting at $8.25 and surging $105 in just 10 days drives investors more to buy into DXYZ. A common mistake made by many new investors is not considering the company&rsquo;s NAV (net asset value). Subsequently, it dropped to as low as $25, still a significant premium of 400% over the reported NAV.</p>



<h2><strong>Private Sector Investing Is Only Heating Up</strong></h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/tech-stocks-1600-300x169.png" alt="A hexagonal grid with different tech-related icons; Tech stocks illustration. Best Tech stocks. tech stocks trading at bargain prices"><div>Source: whiteMocca / Shutterstock</div></div><p>Few funds match the excitement of Destiny Tech100, offering retail investors access to innovative private companies. With top holdings like SpaceX and OpenAI, DXYZ is an exclusive club, albeit with a hefty premium. Despite a recent price drop, enthusiasm remains high.</p>



<p>Many experts have estimated this ETF to have a net asset value (NAV) of around $5 per share, so there may be some valuation concerns, given how far this fund has run. As competition picks up in this space, it&rsquo;s possible this multiple could come down. Thus, I&rsquo;d categorize this company as a speculative buy, for those looking to gain exposure to the private sector. </p>



<p><em>On the date of publication, Chris MacDonald did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.</em></p>
<div><p>Chris MacDonald&rsquo;s love for investing led him to pursue an MBA in Finance and take on a number of management roles in corporate finance and venture capital over the past 15 years. His experience as a financial analyst in the past, coupled with his fervor for finding undervalued growth opportunities, contribute to his conservative, long-term investing perspective.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/05/the-destiny-tech-100-what-you-should-know-before-buying-dxyz-stock/">The Destiny Tech 100: What You Should Know Before Buying DXYZ Stock</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

The Destiny Tech 100: What You Should Know Before Buying DXYZ Stock

Destiny Tech100 reports net asset value per share of $5.07

Destiny Tech100 And The Dark Side Of Investment Democratization

A deep dive into the market's response to Trump's re-election, analyzing top stocks set to gain from his policies. Using a four-pillar approach, we uncover key investment opportunities and sector shifts amid this new mandate.

Trump Stocks Tesla And More Explode: Here's How To Profit.

09:40 EST DESTINY TECH100 (DXYZ) INC trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financia...

DESTINY TECH100 INC trading resumes

Today's trading backdrop features several prominent themes, from monetary policy shifts to geopolitical factors and sector-specific trends.

Trump Trade Continues: TSLA And INTC Explode On Cue

The S&P 500 came into this week having its best Election Year through October since 1936, and the gains have only continued with SPY​​​​​​​ currently up another 4.7% week-to-date.

Election Week 2024 Recap

09:44 EST DESTINY TECH100 (DXYZ) INC trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market...

DESTINY TECH100 INC trading halted, volatility trading pause

09:50 EST DESTINY TECH100 (DXYZ) INC trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financia...

Comments

Destiny Tech100

空売り

Destiny Tech100 (NYSE:DXYZ) 株価情報, 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル